PHARM Optimal-HF Pilot - Trial NCT05623358

Timeline & Enrollment

Primary Outcome

Feasibility of recruitment,Feasibility of achieving rapid optimal medical therapy in intervention arm,Feasibility of patient-reported outcome measure (PROM) collection & participant retention

Summary

The goal if this pilot randomized controlled trial is to determine the feasibility of
 conducting and guide the design of a definitive trial of a pharmacist-led,
 remotely-administered intervention to optimize medications for heart failure (HF) with
 reduced ejection fraction (HFrEF) as part of a multidisciplinary HF clinic.
 
 Both the intervention group and comparator group will receive usual care by the
 multidisciplinary HF clinic, including standard-of-care clinical pharmacy services.
 
 In addition to usual care, participants randomized to the intervention arm will receive
 co-management of medications by a dedicated study pharmacist with advanced training and
 expanded scope of practice, with the aim of achieving optimal medical therapy for HFrEF based
 on the 2021 Canadian Cardiovascular Society HF guidelines. The intervention will consist of
 30-minute remote (virtual or telephone) encounters with the study pharmacist every 1-2 weeks
 with the aim of initiating or titrating ≥1 medication per encounter using standard protocols,
 for an intervention duration of up to 4 months.

ICD-10 Classifications